AiCuris nominates team of researchers from the Universit?tsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative
About AiCuris Anti-infective Cures AG?
AiCuris, a clinical-stage biopharmaceutical company, was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs targeting infectious diseases. PREVYMIS? (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor acting via a novel mechanism of action, was licensed to MSD in 2012 and is approved in the EU, US, Japan, and other parts of the world for the prevention of human CMV infections in adults who received allogeneic hematopoietic stem cell transplantation. The Company has a broad pipeline of clinical-stage and pre-clinical anti-viral and anti-bacterial product candidates. Its wholly owned lead asset, pritelivir, targeting single- or double-resistant herpes simplex virus (HSV) infections, is in phase 3 clinical development. Additional candidates are in development for the treatment of?viruses, such as hepatitis B virus (HBV), adenoviruses and BK virus (BKV), as well as SARS-CoV2 and other viruses with pandemic potential. In the field of antibacterials, AiCuris seeks to develop innovative treatment options for indications with high medical need, including life-threatening, multidrug-resistant, hospital-treated pathogens. Product candidates for antimicrobial resistance (AMR), diabetic foot ulcers and sepsis are in pre-clinical development.
AiCuris is supported by a strong shareholder base, including lead investor SANTO Holding. ?
Company:AiCuris Anti-infective Cures AG Katja Woestenhemke Phone:?+49 202 317 63 0 Email: firstname.lastname@example.org Media relations:MC Services AG Dr. Solveigh M?hler Phone:?+49 211 529 252 19 Email: email@example.com Andreas K?hbacher, PhD Phone: +49 202 317 63 0 Email firstname.lastname@example.org ?
08.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.dgap.de